DOCSLIB.ORG
  • Sign Up
  • Log In
  • Upload
  • Sign Up
  • Log In
  • Upload
  • Home
  • »  Tags
  • »  Actelion

Actelion

  • From the Academy

    From the Academy

  • Annual Report on Annual Reports 2016

    Annual Report on Annual Reports 2016

  • Sales of $20.7 Billion Reflecting Growth of 1.9%, Operational Growth of 3.2

    Sales of $20.7 Billion Reflecting Growth of 1.9%, Operational Growth of 3.2

  • FDA Listing of Authorized Generics As of July 1, 2021

    FDA Listing of Authorized Generics As of July 1, 2021

  • Annual Report

    Annual Report

  • Johnson & Johnson Annonce Que L'exécution De L'offre Publique D

    Johnson & Johnson Annonce Que L'exécution De L'offre Publique D

  • HIGHLIGHTS of PRESCRIBING INFORMATION TRACLEER® (Bosentan) Tablets These Highlights Do Not Include All the Information Needed to Use TRACLEER Safely and Effectively

    HIGHLIGHTS of PRESCRIBING INFORMATION TRACLEER® (Bosentan) Tablets These Highlights Do Not Include All the Information Needed to Use TRACLEER Safely and Effectively

  • 2016 Annual Report

    2016 Annual Report

  • Partner with DNA

    Partner with DNA

  • Swiss Biotech Success Stories Award Winner 2020 Actelion

    Swiss Biotech Success Stories Award Winner 2020 Actelion

  • Selected Pharmaceuticals in Late Stage U.S. and E.U

    Selected Pharmaceuticals in Late Stage U.S. and E.U

  • 95879-Medadnews-Nove

    95879-Medadnews-Nove

  • Research Annual Report

    Research Annual Report

  • Johnson & Johnson

    Johnson & Johnson

  • Appendix B - Product Name Sorted by Applicant

    Appendix B - Product Name Sorted by Applicant

  • Manufacturers and Wholesalers Street City ST Zip Acorda Therapeutics

    Manufacturers and Wholesalers Street City ST Zip Acorda Therapeutics

  • Results from Randomized Phase II Core and Extension Studies in Relapsing‑Remitting Multiple Sclerosis Mark S

    Results from Randomized Phase II Core and Extension Studies in Relapsing‑Remitting Multiple Sclerosis Mark S

  • Cancellation of Publicly Held Actelion Shares and Delisting from SIX Swiss Exchange As of November 7, 2017

    Cancellation of Publicly Held Actelion Shares and Delisting from SIX Swiss Exchange As of November 7, 2017

Top View
  • Drug Companies Participating in MED-Project Stewardship Plan (February 9, 2017)
  • Actelion Follows Innovation Into GP Markets Switzerland’S Actelion Has Become Europe’S Most Successful Biotech in Large Part Thanks to PAH Treatment Tracleer
  • Abbott Abbvie Acpeth Actelion Pharmaceuticals Air Liquide
  • FULL NAME Contact Company ID Email 3M Company Suzanne Danielson CC0013 [email protected] 3M Unitek Corporation Vincent Martinez CC0361 [email protected] A-Dec, Inc
  • Affiliate Rewards Eligible Companies
  • Idorsia Announces Financial Results for the First Half 2021 – Building Momentum Towards Becoming a Fully-Fledged Biopharmaceutical Company
  • Clarity on Mergers & Acquisitions
  • For Relapsing Forms of Multiple Sclerosis
  • TRACLEER (Bosentan)
  • J&J / Actelion Regulation
  • Offer Prospectus English
  • Johnson & Johnson
  • Idorsia Financial Report 2020
  • Financial Report Full Year 2017
  • J&J's $30Bn for Actelion Buys Immediate and Longer-Term Value
  • Johnson & Johnson
  • Provider Manual
  • Questionnaire on Johnson and Johnson Products


© 2024 Docslib.org    Feedback